Tubal Precursor Lesions for High-Grade Serous Ovarian Carcinoma

被引:0
作者
Meleis, Mahmoud Hanafy [1 ]
El-Agwany, Ahmed Mohammed Samy [1 ]
机构
[1] Alexandria Univ, El Shatby Matern Univ Hosp, Fac Med, Dept Obstet & Gynecol, Alexandria, Egypt
关键词
Serous carcinoma; Ovarian cancer; P53; Immunostaining; Peritoneal cancer; BRCA1; BRCA2;
D O I
10.1007/s40944-015-0031-3
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background Ovarian cancer is the most common fatal cancer of the female reproductive tract in industrialized countries; it is diagnosed annually in more than 200,000 women worldwide, with the greatest incidence in the USA and Northern Europe, and lowest incidence in Africa and Asia. Aim of the work To show whether the fallopian tube could be the site of origin of pelvic carcinomas. Patients This study included 36 patients with high-grade serous ovarian carcinoma. The patients were selected from the Gynecology Clinic in El-shatby University Maternity Hospital. All patients underwent laparotomy for cytoreduction and staging in Gynecology Department, and all biopsies were sent for histopathology, and patients diagnosed to be high-grade serous ovarian carcinoma were included in our study. Inclusion criteria were high-grade serous-type ovarian cancer selected after laparotomy and histopathological examination. Exclusion criteria were benign adnexal mass, low-grade tumor and other types of ovarian tumors. Methods All patients were subjected to preoperative analysis (history taking, clinical evaluation, ultrasound abdomen and pelvis, for estimation of morphological index, CT scan, assessment of CT peritoneal cancer index PCI and Serum CA125 assessment). Intraoperative peritoneal wash or ascites fluid aspiration, total abdominal hysterectomy with bilateral salpingo-oophorectomy, omentectomy, either supra-or infra-colonic and lymphadenectomy (pelvic, para-aortic) if suspicious were done, and pathological examination (gross examination and histopathological examination) and immunostaining were done. Results Histopathological diagnosis of the tubal lesions through examination of the H& E sections of the distal part of the tube in the studied groups revealed either normal tube with no remarkable changes, hyperplastic changes or tubal intraepithelial neoplasia. In the serous group, 21.4 % of the cases were normal, 69.6 % showed hyperplastic changes, and 9 % were TIN. The non-serous group showed 30.8 % of the cases were normal, 69.2 % showed hyperplastic changes, and no one showed TIN. While the control group showed 83.3 % were normal, 16.7 % showed hyperplastic changes and no one showed TIN. There was a significant difference between serous and control as well as between non-serous and control. In the low-grade group, about 11.1 % of the cases showed no pathological changes, 89.9 % showed hyperplastic changes, and no one showed TIN. While in the high-grade group, 26.3 % of the cases showed no pathological changes, 60.5 % showed hyperplastic changes, and 13.2 % showed TIN. The difference between high-and low-grade serous tumors was statistically significant. Results of immunohistochemical staining for P53 in tubal sections revealed that in the serous group, 5 cases (8.9 %) showed negative staining, 22 cases (39.3 %) showed focal positive staining, and 29 cases (51.8 %) showed diffuse positive staining. In the non-serous group, 8 cases (30.8 %) showed negative staining and 18 cases (69.2 %) showed positive focal. No cases showed diffuse positive staining. In control group, 15 cases (83.3 %) showed negative staining and 3 cases (16.7 %) showed focal positive staining. No cases showed diffuse positive staining. There was significant difference between serous and non-serous, serous and control as well as nonserous and control. In the low-grade group, 1 case (10.6 %) showed negative staining, 17 cases (89.4 %) showed positive focal staining, and no cases showed diffuse positive staining. In high-grade group, 4 cases (5.5 %) showed negative staining, 5 cases (18.2 %) showed focal positive staining, and 29 cases (76.3 %) showed diffuse positive staining. Conclusion and recommendations We concluded that fallopian tube could be a site of origin of pelvic carcinoma. We recommend that risky females after completion of their family size should undergo prophylactic salpingectomy to reduce risk of pelvic cancers.
引用
收藏
页数:9
相关论文
共 42 条
  • [1] BARTEK J, 1990, ONCOGENE, V5, P893
  • [2] MUTATIONAL SPECTRA AND IMMUNOHISTOCHEMICAL ANALYSES OF P53 IN HUMAN CANCERS
    BENNETT, WP
    HOLLSTEIN, MC
    HSU, IC
    SIDRANSKY, D
    LANE, DP
    VOGELSTEIN, B
    HARRIS, CC
    [J]. CHEST, 1992, 101 (03) : S19 - S20
  • [3] Disruption of p53 in human cancer cells alters the responses to therapeutic agents
    Bunz, F
    Hwang, PM
    Torrance, C
    Waldman, T
    Zhang, YG
    Dillehay, L
    Williams, J
    Lengauer, C
    Kinzler, KW
    Vogelstein, B
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) : 263 - 269
  • [4] Aberrant Nuclear p53 Expression Predicts Hemizygous 17p (TP53) Deletion in Chronic Lymphocytic Leukemia
    Chang, Hong
    Jiang, Allan M.
    Qi, Connie X. Y.
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2010, 133 (01) : 70 - 74
  • [5] Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer
    Crum, Christopher P.
    Drapkin, Ronny
    Kindelberger, David
    Medeiros, Fabiola
    Miron, Alexander
    Lee, Yonghee
    [J]. CLINICAL MEDICINE & RESEARCH, 2007, 5 (01) : 35 - 44
  • [6] The distal fallopian tube: a new model for pelvic serous carcinogenesis
    Crum, Christopher P.
    Drapkin, Ronny
    Miron, Alexander
    Ince, Tan A.
    Muto, Michael
    Kindelberger, David W.
    Lee, Yonghee
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2007, 19 (01) : 3 - 9
  • [7] Bringing the p53 Signature Into Focus
    Crum, Christopher P.
    Xian, Wa
    [J]. CANCER, 2010, 116 (22) : 5119 - 5121
  • [8] ACTIVATING MUTATIONS FOR TRANSFORMATION BY P53 PRODUCE A GENE-PRODUCT THAT FORMS AN HSC70-P53 COMPLEX WITH AN ALTERED HALF-LIFE
    FINLAY, CA
    HINDS, PW
    TAN, TH
    ELIYAHU, D
    OREN, M
    LEVINE, AJ
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (02) : 531 - 539
  • [9] Precursors to pelvic serous carcinoma and their clinical implications
    Folkins, Ann K.
    Jarboe, Elke A.
    Roh, Michael H.
    Crum, Christopher P.
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 113 (03) : 391 - 396
  • [10] Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary
    Gershenson, David M.
    Sun, Charlotte C.
    Lu, Karen H.
    Coleman, Robert L.
    Sood, Anil K.
    Malpica, Anais
    Deavers, Michael T.
    Silva, Elvio G.
    Bodurka, Diane C.
    [J]. OBSTETRICS AND GYNECOLOGY, 2006, 108 (02) : 361 - 368